Seeking Alpha

Bristol-Myers submits NDAs for Hep C drugs

  • Bristol-Myers Squibb (BMY +0.2%) submits new drug applications to the FDA for its NS5A replication complex inhibitor daclatasvir (DVC) and its NS3 protease inhibitor asunaprevir (ASV) for the treatment of Hepatitis C.
  • The regulatory agency recently designated the drugs Breakthrough Therapies.
  • The European Medicines Agency and Japan's Pharmaceutical and Medical Devices Agency are also reviewing the products under accelerated processes.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|